Chris Acevedo, CPA/MBA

Chief Financial Officer
Mr. Acevedo, CFO of OS Therapies Inc. since 2023, is a seasoned financial expert with extensive experience in accounting, M&A, and business strategy. A CPA and University of Delaware graduate, he also runs a successful CPA firm and brings expertise in finance, IT, HR, and taxation.
See full team
Chris Acevedo
Background

Mr. Acevedo has been CFO of OS Therapies Inc. since July 2023, previously serving as lead accountant and interim CFO since June 2020. A Cape May County, NJ native, he founded his first business at 17. Since 2010, he has operated a CPA firm managing OS Therapies’ accounting. He previously held CFO roles at five companies ($10MM–$50MM revenue) and has expertise in M&A, finance, IT, HR, and taxation. He holds CPA certifications in Delaware, Maryland, and Pennsylvania and earned an M.B.A. and B.S. in Accounting from the University of Delaware. He resides in Delaware and enjoys golf, reading, and the outdoors.

Our Pipeline

The Future of Cancer Treatment

OS Therapies is not just addressing Osteosarcoma. With the other uses of our HER2 target cancer immunotherapy and the addition of our OST-tADC tunable Antibody Drug Conjugate silicone linker platform, we are paving the way for the next-generation of cancer treatments.
Female chemist working on osteosarcoma treatments | OS TherapiesLab technician working on cancer treatments | OS TherapiesFemale chemist working on cancer treatments